These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling.

Drug Details

Company Name	Business Partner	Drug Name	Generic Name	Unique ID	Studied Indications or Disease	Phase	Approved Drug Label
Abbott Laboratories		Biaxin	Clarithromycin	FRAN-02-002	Acute bacterial exacerbations of chronic bronchitis	Phase IV	http://rxabbott.com /u4_prescribing_info.cfm
Clinical Study Summary	Protocol No. FRAN-02-002: Efficacy and sa clarithromycin (5-day short-course) vs telith exacerbation of chronic bronchitis						
	Perronne C, Drugeon H, Zuck P, et al. Effic release clarithromycin (5-day short-course) bacterial exacerbation of chronic bronchitis http://france.elsevier.com/direct/MEDMAL DOI:10.1016/j.medmal.2005.07.002	vs telithromycin, in acute					
	Abbott Laboratories (Abbott) will use reason accurate and up-to-date information, consis procedures, on the ClinicalStudyResults.or among other reasons, the status of studies make no, and makes no, warranties or repr the currency or completeness of the inform Persons accessing and using information p ClinicalStudyResults.org web site do so at all warranties, express or implied, including of fitness for a particular purpose. Abbott sl damages, including without limitation, direct indirect or punitive damages, arising out of use information posted by Abbott on the Cli site, or any errors or omissions in the conter	stent with Abbott policies and g web site. However, because, often changes, Abbott can resentations of any kind as to ation contained therein. rosted by Abbott on the their own risk. Abbott disclaims warranties of merchantability hall not be liable for any t, incidental, consequential, access to, use of, or inability to inicalStudyResults.org web					
Company	No document provided.						

Study